Steve Schonfeld’s Ovid Therapeutics OVID Stock Holding History

Steve Schonfeld’s Portfolio OVID Stock Details OVID Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$94.3K	Sell	35,049 -177,162	-83%	-$457K	﹤0.01%	2316
2026 Q1	$471K	Buy	212,211 +19,715	+10%	+$35.2K	﹤0.01%	1409
2025 Q4	$314K	Sell	192,496 -690,658	-78%	-$1.06M	﹤0.01%	1564
2025 Q3	$1.15M	Buy	+883,154	New	+$765K	0.01%	1303
2021 Q4	–	Sell	-10,100	Closed	-$34K	–	2428
2021 Q3	$34K	Buy	+10,100	New	+$36.8K	﹤0.01%	2020
2021 Q2	–	Sell	-64,000	Closed	-$257K	–	2203
2021 Q1	$257K	Buy	+64,000	New	+$213K	﹤0.01%	1393
2018 Q2	–	Sell	-20,520	Closed	-$145K	–	912
2018 Q1	$145K	Hold	20,520	–	–	0.01%	700
2017 Q4	$203K	Sell	20,520 -12,980	-39%	-$119K	0.02%	672
2017 Q3	$287K	Sell	33,500 -1,500	-4%	-$12.5K	0.03%	460
2017 Q2	$367K	Buy	+35,000	New	+$457K	0.04%	443

Other funds holding OVID

Jupiter Topco New York $245B AUM

EAM

Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

ACM

ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Steve Schonfeld's OVID Position: Q2 2026 in Review

Steve Schonfeld reduced its Ovid Therapeutics (OVID) stake by 83% in Q2 2026, selling an estimated $457K and leaving 35,049 shares worth $94.3K. The position accounts for ﹤0.01% of the portfolio, ranked #2316.

Steve Schonfeld first reported a position in OVID in Q2 2017 and has held it in 10 quarters since. The position peaked at $1.15M in Q3 2025. 130 funds tracked by Wall St. Rank hold OVID as of Q2 2026.

Steve Schonfeld held 35,049 shares of Ovid Therapeutics worth $94.3K as of Q2 2026.
Steve Schonfeld sold 177,162 Ovid Therapeutics shares in Q2 2026, an estimated $457K.
Ovid Therapeutics made up ﹤0.01% of Steve Schonfeld's portfolio in Q2 2026, its #2316 holding.
Steve Schonfeld first reported a position in Ovid Therapeutics in Q2 2017 and has held it in 10 quarters since.
Steve Schonfeld's Ovid Therapeutics position peaked at $1.15M in Q3 2025.
130 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q2 2026.

Based on Schonfeld Strategic Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.